MedPath

CURON BIOPHARMACEUTICAL (AUSTRALIA) CO PTY LTD

🇦🇺Australia
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:1

Trial Phases

1 Phases

Phase 1:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 1
3 (100.0%)

A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies

Phase 1
Conditions
Locally Advanced Solid Tumor
Metastatic Solid Tumor
Hematologic Malignancies
Interventions
First Posted Date
2021-08-31
Last Posted Date
2021-08-31
Lead Sponsor
Curon Biopharmaceutical (Australia) Co Pty Ltd
Target Recruit Count
164
Registration Number
NCT05028478

A Study of CN1 in Combination With CN401 in Adult Patients With Relapsed/Refractory Lymphoid Malignancies

Phase 1
Terminated
Conditions
Relapsed Lymphoid Malignancies
Refractory Lymphoid Malignancies
Interventions
Drug: CN1, 0.5mg/kg and CN401, 400mg
Drug: CN1, 1mg/kg and CN401, 800mg
Drug: CN1, 10mg/kg and CN401, 800mg
Drug: CN1, 1mg/kg and CN401, 600mg
Drug: CN1, 3mg/kg and CN401, 800mg
First Posted Date
2021-05-10
Last Posted Date
2022-10-24
Lead Sponsor
Curon Biopharmaceutical (Australia) Co Pty Ltd
Target Recruit Count
7
Registration Number
NCT04880564
Locations
🇦🇺

Monash Health - Monash Medical Centre, Bentleigh, Victoria, Australia

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1

Phase 1
Completed
Conditions
Advanced Solid Tumor
B Cell Lymphoma
Interventions
First Posted Date
2020-06-05
Last Posted Date
2021-10-18
Lead Sponsor
Curon Biopharmaceutical (Australia) Co Pty Ltd
Target Recruit Count
13
Registration Number
NCT04418141
Locations
🇦🇹

Mater Medical Centre, Brisbane, Queensland, Austria

News

No news found
© Copyright 2025. All Rights Reserved by MedPath